ArticleFrontiers in medicine2025
Global burden of lung cancer in adolescents and adults aged 15-45: analysis of the global burden of disease study (1990-2021).
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Publication Characteristics and Reporting Quality of GBD-Derived Burden of Disease Studies: A Cross-Sectional Analysis of Lung Cancer.Journal of evidence-based medicine · 2026Article
- Rising burden of early-onset lung cancer among Chinese adolescents and young adults (1990-2023): a Bayesian age-period-cohort analysis with projections to 2038.Frontiers in medicine · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lung cancer is a leading cause of cancer-related deaths around the world, but its impact on young and middle-aged individuals (aged 15-45 years) is less understood. The aim of this study was to assess the global burden of lung cancer in those aged 15-45 years during 1990-2021. Methods: This study estimated global trends in prevalence, mortality, and disability-adjusted life years (DALYs) associated with lung cancer in this age group. The Global Burden of Disease Study 2021 was utilized to analyze data from 1990 to 2021. We examined variations by sex, age subgroup, sociodemographic index (SDI), and region and assessed key risk factors contributing to DALYs. Results: Our findings reveal that while the number of lung cancer cases aged 15-45 increased by 22.1%, the age-standardized prevalence decreased by 23.9%; age-standardized mortality and DALYs declined significantly over the past three decades. The decrease was more evident among men than women, despite men having a higher overall disease burden. In high-SDI countries, prevalence and DALYs experienced substantial decreases, whereas low-SDI countries experienced increases, particularly among women. East Asia demonstrated a high disease burden. Smoking was identified as the most prominent risk factor, especially in high-middle SDI countries. Household air pollution and ambient particulate matter pollution came after it. Conclusion: The study underscores the effectiveness of tobacco control measures and early screening in reducing lung cancer burden among young and middle-aged individuals. Nevertheless, the upward trends in low - SDI countries emphasize the necessity for interventions that are specifically aimed at environmental risk factors and smoking cessation initiatives. These findings provide valuable insights for policymakers and healthcare providers aiming to implement strategies to further cut down the global burden of lung cancer in the younger population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.